Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule

被引：0
|
作者：
M. Santisteban
Y. Nieto
S. De la Cruz
J. Aristu
J. L. Zubieta
O. Fernández Hidalgo
机构：
[1] Clínica Universitaria de Navarra,Departmento de Oncología Médica
[2] Clínica Universitaria de Navarra,Departamento de Radioterapia
[3] Clínica Universitaria de Navarra,Servicio de Radiología
来源：
Clinical and Translational Oncology | 2007年 / 9卷
关键词：
CNS; Lymphoma; HDMTX; Rituximab; Temozolomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity.
引用
收藏
页码：465 / 467
页数：2
相关论文
共 50 条
  • [31] Rituximab as a Second-Line Treatment for lymphocytic Vasculitis of the Central Nervous System
    Anis, Saar
    Sharabi, Amir
    Mina, Yair
    Klein, Ainat
    Cagnano, Emanuela
    Elkayam, Ori
    Gurevich, Tanya
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2016, 18 (10): : 630 - 632
  • [32] Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
    Hoang, G. H. Nguyen
    Nguyen, P. T. B.
    Nguyen, H. T. N.
    Do, K. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma
    Prakash Ambady
    Rongwei Fu
    Laszlo Szidonya
    David M. Peereboom
    Nancy D. Doolittle
    Edward A. Neuwelt
    Journal of Neuro-Oncology, 2020, 147 : 171 - 176
  • [34] Effect of rituximab on primary central nervous system lymphoma: a meta-analysis
    Yue Song
    Yibo Wen
    Weili Xue
    Yanjie Zhang
    Mingzhi Zhang
    International Journal of Hematology, 2017, 106 : 612 - 621
  • [35] Cytomegalovirus Meningoencephalitis After Rituximab Treatment for Primary Central Nervous System Lymphoma
    Siakantaris, Marina P.
    Argyropoulos, Kimon V.
    Ioannou, Savvas
    Papadopoulou, Vasiliki
    Tzeletas, George
    Tsonis, John
    Dimitrakopoulou, Aglaia
    Yiannopoulou, Konstantina G.
    Pangalis, Gerassimos A.
    Vaiopoulos, George
    NEUROLOGIST, 2015, 19 (02) : 35 - 37
  • [36] Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma
    Ambady, Prakash
    Fu, Rongwei
    Szidonya, Laszlo
    Peereboom, David M.
    Doolittle, Nancy D.
    Neuwelt, Edward A.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 147 (01) : 171 - 176
  • [37] Rituximab with high-dose methotrexate in primary central nervous system lymphoma
    Kansara, Roopesh
    Shenkier, Tamara N.
    Connors, Joseph M.
    Sehn, Laurie H.
    Savage, Kerry J.
    Gerrie, Alina S.
    Villa, Diego
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (12) : 1149 - 1154
  • [38] Effect of rituximab on primary central nervous system lymphoma: a meta-analysis
    Song, Yue
    Wen, Yibo
    Xue, Weili
    Zhang, Yanjie
    Zhang, Mingzhi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (05) : 612 - 621
  • [39] Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma
    Kinslow, Connor J.
    Rae, Ali, I
    Neugut, Alfred, I
    Adams, Christopher M.
    Cheng, Simon K.
    Sheth, Sameer A.
    McKhann, Guy M.
    Sisti, Michael B.
    Bruce, Jeffrey N.
    Iwamoto, Fabio M.
    Sonabend, Adam M.
    Wang, Tony J. C.
    BRITISH JOURNAL OF NEUROSURGERY, 2020, 34 (06) : 690 - 696
  • [40] Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiaiton temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results
    Glass, Jon
    Won, Minhee
    Schultz, Christopher J.
    Brat, Daniel
    Bartlett, Nancy
    Suh, John H.
    Fisher, Barbara Jean
    Liepman, Marcia K.
    Mehta, Minesh P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345